Phase 3 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 80 years old.
- People who are able to understand the study and are willing to sign a consent form.
- People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scoring system (called ECOG, scored 0–2).
- People who have been diagnosed with advanced pancreatic adenocarcinoma (a specific type of pancreatic cancer), confirmed through laboratory testing of tissue or cells.
- People with locally advanced pancreatic cancer (cancer that has grown but has not spread widely to distant parts of the body).
- People whose cancer has not stopped responding to previous chemotherapy, and who have not previously received radiotherapy.
- People whose blood marker called CA19-9 was above 37 U/mL at the start of chemotherapy, and then dropped to within the normal range (37 U/mL or below) after chemotherapy.
- People who have at least one measurable area of cancer, as assessed using standard imaging guidelines (called RECIST criteria).
- People whose expected survival is at least 3 months.
- People whose kidney, liver, and other organ function meets the required levels based on blood test results.
- Women who could become pregnant, and men, must agree to use adequate contraception throughout the study period.
Who may not be able to join:
- Women who are pregnant or currently breastfeeding.
- People whose cancer is classified as a primary pancreatic cancer that has not advanced (confirm with trial site).
- People whose CA19-9 blood marker level was 37 U/mL or below at the start of the study.
- People whose cancer has been confirmed by laboratory testing to be a type other than adenocarcinoma of the pancreas.
- People who have inflammation of the digestive system, such as pancreatitis (inflammation of the pancreas), cholecystitis (inflammation of the gallbladder), or cholangitis (inflammation of the bile ducts).
- People with severe or uncontrolled health conditions that could affect their ability to follow the study plan or make the results harder to interpret.
- People with kidney disease or who require dialysis.
- People with other serious health conditions that, in the opinion of the treating doctor, could significantly affect the safety of the treatment.
- People who have a known allergy to oxaliplatin or other chemotherapy medicines used in the study.
- People who are unwilling or unable to follow the study procedures.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Guopei Luo, MD, Fudan University
Phone: 86 64175590
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
progression-free survival, PFS
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.